Meaningful and durable increases in functional neutrophils observed over 6-month trial with oral once-daily mavorixafor ...

Poster presentations across all programs, including data from HELIOS long-term extension trial of bitopertin in ...

Revumenib abstracts highlight compelling results in acute leukemia across the frontline and R/R setting and multiple genetic populations, including mNPM1, KMT2Ar, and NUP98r – – Axatilimab abstracts ...

ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today ...

Data contribute to growing body of support around the anti-fibrotic activity of EFX in patients with pre-cirrhotic MASH SOUTH SAN FRANCISCO, Calif., May 10, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics ...

Forge Biologics ("Forge"), a leading manufacturer of genetic medicines and member of the Ajinomoto Bio-Pharma Services group, today announced that it will deliver eight presentations at the upcoming ...

The company is presenting data related to its medications designed to advance the prevention and treatment of asthma and COPD.

PRESS RELEASE AB SCIENCE TO PRESENT NEW DATA FROM MASITINIB CLINICAL PROGRAM IN AMYOTROPHIC LATERAL SCLEROSIS IN TWO PRESENTATIONS AT THE 2025 ENCALS ANNUAL MEETING MASITINIB REDUCES SERUM ...

Interested contributors now have until 19 May 2025 to submit abstracts for the IAEA's International Conference on Emergency Preparedness and Response.

Session A-2 Room 339: Leverage AI in Psychology: Finding a Use Case Presentation 1: Finding a Use Case: Building a Scheduling GPT: Olivia Velez, Psychology Presentation 2: Finding a Use Case: Natural ...

All oral presentations will be made on Wednesday, May 14, as will two of the four poster presentations ... treatments to these communities who so desperately need them.” Abstracts can be accessed ...